Aristotle Atlantic Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aristotle Atlantic Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,032	Closed	-$283K	–	91
2024 Q3	$283K	Sell	4,032 -29,278	-88%	-$2.45M	0.01%	88
2024 Q2	$2.74M	Sell	33,310 -760	-2%	-$63.3K	0.09%	75
2024 Q1	$2.98M	Sell	34,070 -1,260	-4%	-$113K	0.1%	74
2023 Q4	$3.41M	Buy	35,330 +521	+1%	+$46.1K	0.12%	74
2023 Q3	$3.08M	Buy	34,809 +11,837	+52%	+$1.05M	0.12%	75
2023 Q2	$1.99M	Buy	22,972 +17,491	+319%	+$1.65M	0.08%	81
2023 Q1	$533K	Buy	+5,481	New	+$568K	0.03%	90
2021 Q3	–	Sell	-25,000	Closed	-$2.09M	–	100
2021 Q2	$2.09M	Hold	25,000	–	–	0.14%	77
2021 Q1	$1.89M	Hold	25,000	–	–	0.14%	77
2020 Q4	$2.19M	Hold	25,000	–	–	0.17%	72
2020 Q3	$1.9M	Hold	25,000	–	–	0.17%	68
2020 Q2	$3.08M	Hold	25,000	–	–	0.3%	47
2020 Q1	$2.11M	Hold	25,000	–	–	0.32%	43
2019 Q4	$2.11M	Hold	25,000	–	–	0.27%	48
2019 Q3	$1.69M	Hold	25,000	–	–	0.49%	40
2019 Q2	$2.14M	Hold	25,000	–	–	0.62%	30
2019 Q1	$2.22M	Hold	25,000	–	–	0.67%	29
2018 Q4	$2.13M	Sell	25,000 -200	-0.8%	-$19K	0.75%	29
2018 Q3	$2.42M	Hold	25,200	–	–	1.48%	22
2018 Q2	$2.37M	Sell	25,200 -7,200	-22%	-$631K	0.82%	29
2018 Q1	$2.63M	Hold	32,400	–	–	0.95%	24
2017 Q4	$2.89M	Buy	+32,400	New	+$2.82M	1.04%	20

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Aristotle Atlantic Partners's BMRN Position: Q4 2024 in Review

Aristotle Atlantic Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 4,032 shares — an estimated $283K sold.

Aristotle Atlantic Partners first reported a position in BMRN in Q4 2017 and held it in 22 quarters. The position peaked at $3.41M in Q4 2023. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

Aristotle Atlantic Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Aristotle Atlantic Partners sold 4,032 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $283K.
Aristotle Atlantic Partners first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 22 quarters.
Aristotle Atlantic Partners's BioMarin Pharmaceuticals position peaked at $3.41M in Q4 2023.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Aristotle Atlantic Partners's 13F filing for Q4 2024, filed 14 Feb 2025.